Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses advancements and future directions in the treatment of benign prostatic hyperplasia, highlighting ongoing clinical trials of novel techniques, but it reports no new clinical results.

This opinion article reviews various pathways through which onabotulinumtoxinA might work in medical treatments, highlighting applications beyond muscle paralysis, including pain inhibition and potential effects on hair loss and cancer cell apoptosis.

This review evaluates traditional uses, phytochemical profiles, and pharmacological activities of Mediterranean Erica species, revealing the wide range of bioactive compounds and highlighting their antioxidant, anti-inflammatory, and antimicrobial activities. Further studies are suggested to fully understand their medicinal potential.

This chapter reviews the diverse and interrelated consequences of obesity on physical, metabolic, reproductive, psychosocial, and economic health without reporting any new clinical results.

This study found that social hair plucking in captive rhesus macaques is linked to alopecia and possibly relates to stress in females.

This review summarizes recent research on the molecular properties and functions of L-PGDS and PGD2, but reports no new findings, highlighting their pathophysiological roles and guiding future studies.

This review discusses the challenges and considerations in managing transgender patients in critical care, noting gaps in current medical curricula and suggesting improvements in education.

Benign Prostatic Hyperplasia may be caused by changes in how the body processes male hormones.

This review discusses recent developments in α1-adrenoceptor antagonists and 5α-reductase inhibitors for treating benign prostatic hyperplasia, reporting no new clinical results while identifying potential areas for future drug development.

Finasteride slightly improves prostate symptoms but has minimal difference from placebo.

This review analyzes existing literature on prognostic factors for renal cell carcinoma, highlighting the need for continuous updates of prognostic models to reflect advancement in molecular pathway knowledge and targeted therapies.

This article discusses the BJUI's strategies to support urology-related clinical trials but reports no new experimental results; the authors emphasize the importance of rigorous trial design and reporting standards.

Minoxidil absorbs poorly through skin, with low risk of side effects at 1-2% concentration.

This review discusses current anti-inflammatory treatment options for calcium pyrophosphate crystal deposition disease (CPPD) and highlights the lack of crystal-targeted therapies, emphasizing the need for more research to guide treatment.

This study found that finasteride was nongenotoxic in Drosophila, while doxazosin mesylate and saw palmetto induced homologous recombination, indicating potential genotoxic actions under the test conditions.

Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.

In this study, radial shockwave therapy significantly improved muscle spasticity, ankle range of motion, and functional abilities in children with spastic cerebral palsy, suggesting it may help them achieve greater autonomy in daily activities.

In this study, the n-hexane fraction of Carthamus oxyacantha methanolic extract exhibited significant 5α-reductase inhibitory activity in vitro, suggesting potential therapeutic use for benign prostatic hyperplasia through DHT inhibition.

This case study describes a rare presentation of childhood lupus with recurrent pericardial effusion and cardiac tamponade that responded to glucocorticoid therapy.

Finasteride effectively inhibits 5α reductase, while plant extracts like Permixon and Bazoton don't show significant results.

Finasteride helps regrow hair and shrink prostate by reducing DHT, with some sexual side effects.

This study found that finasteride significantly reduced symptom severity scores in patients with inflammatory chronic pelvic pain syndrome, though its effect on pain was not significant.

This study observed that finasteride use among men with benign prostatic hyperplasia was associated with a decreased incidence of low-grade prostate cancer but not high-grade tumors.

This study suggests that true binary and ternary inclusion complexes were formed between finasteride and 2-hydroxypropyl-ß-cyclodextrin, with or without the addition of specific polymers.

This study suggests that a larger prostate is associated with a higher prevalence of androgenetic alopecia, although the prostate size did not correlate with alopecia severity.

This study found that using drug microplates in transdermal finasteride films enhances aqueous solubility and skin permeation compared to films with pure finasteride.

In this study, there was no evidence that using 5α-reductase inhibitors for either short or long durations increased the risk of male breast cancer.

This review discusses the potential uses of 5α-reductase inhibitors for conditions ranging from benign prostatic hyperplasia to skin disorders like acne and male pattern baldness, but it reports no new clinical results.

This review summarizes recent advancements in steroidal 5α-reductase inhibitors for benign prostatic hyperplasia and reports no new clinical results.

This study found that a transdermal delivery system using 3% azone and P407 gel may enhance the skin permeation of doxazosin and finasteride for treating benign prostatic hyperplasia.